Protagonist Therapeutics Inc
XBER:PGF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Protagonist Therapeutics Inc
XBER:PGF
|
US |
|
J
|
Japan Tobacco Inc
OTC:JAPAY
|
JP |
|
Mitsubishi Electric Corp
F:MIE
|
JP |
|
S
|
Shanghai Pharmaceuticals Holding Co Ltd
OTC:SHPMY
|
CN |
|
R
|
Regeneron Pharmaceuticals Inc
XBER:RGO
|
US |
|
Woodward Inc
NASDAQ:WWD
|
US |
Protagonist Therapeutics Inc
Protagonist Therapeutics is a drug-development company that designs peptide-based medicines, which are short chains of amino acids built to act like natural signals in the body. Its work is focused on diseases where immune pathways or blood-related signals need to be carefully controlled, and its main value comes from advancing drug candidates through research and clinical testing rather than from selling products today. The company’s customers are mainly large pharmaceutical partners, doctors, and patients in the future if its medicines win approval. It makes money through collaboration and licensing deals, research support from partners, and potentially future payments tied to sales or royalties if its drug programs succeed. In that sense, it acts as an inventor and development partner, not a mass manufacturer or retailer. What sets Protagonist apart is its focus on peptide therapeutics, a drug class that sits between small-molecule drugs and biologics. Peptides can be designed to hit specific biological targets with a high degree of precision, and that gives the company a narrower but more specialized role in the drug pipeline. Investors should think of it as a biotech platform company whose business depends on turning scientific programs into partner-backed or commercial medicines.
Protagonist Therapeutics is a drug-development company that designs peptide-based medicines, which are short chains of amino acids built to act like natural signals in the body. Its work is focused on diseases where immune pathways or blood-related signals need to be carefully controlled, and its main value comes from advancing drug candidates through research and clinical testing rather than from selling products today.
The company’s customers are mainly large pharmaceutical partners, doctors, and patients in the future if its medicines win approval. It makes money through collaboration and licensing deals, research support from partners, and potentially future payments tied to sales or royalties if its drug programs succeed. In that sense, it acts as an inventor and development partner, not a mass manufacturer or retailer.
What sets Protagonist apart is its focus on peptide therapeutics, a drug class that sits between small-molecule drugs and biologics. Peptides can be designed to hit specific biological targets with a high degree of precision, and that gives the company a narrower but more specialized role in the drug pipeline. Investors should think of it as a biotech platform company whose business depends on turning scientific programs into partner-backed or commercial medicines.
Pipeline Expansion: Protagonist now has five new chemical entities in six clinical studies, spanning blood disorders, IBD, and autoimmune diseases.
Lead Program Progress: Rusfertide (PTG-300) showed promising Phase 2 results in polycythemia vera (PV), with improved hematocrit control and reduced phlebotomy needs.
Upcoming Milestones: Rusfertide’s pivotal trial in PV is expected to be a key 2021 event; regulatory consultations are ongoing, and Phase 2 enrollment should complete by mid-2021.
Collaborative Success: Janssen partnership continues to advance, with three IL-23 receptor antagonists in development and additional milestone payments earned.
Financials: 2020 revenue rose sharply to $28.6 million, driven by the Janssen collaboration, while net loss narrowed to $66.2 million from $77.2 million last year.
Strong Cash Position: Ended 2020 with $307.8 million in cash and equivalents; funding expected to cover operations through mid-2024.
